DDDD 4d Pharma Plc

TIDMDDDD

RNS Number : 9029C

4d Pharma PLC

20 June 2019

4D pharma plc

(the "Company" or "4D")

Result of AGM

At the annual general meeting of 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, held earlier today, all resolutions put to shareholders were duly passed.

The full text of each resolution was included in the notice of the meeting, which was posted to shareholders on 28 May 2019, and is available on the Company's website www.4dpharmaplc.com.

The proxy scores for the resolutions will shortly be available on the Company's website www.4dpharmaplc.com.

For further information please contact:

 
 4D 
 Duncan Peyton, Chief Executive Officer          + 44 (0)113 895 0130 
  Fay Weston, Head of Investor Relations          + 44 (0)7990 381713 
 Zeus Capital Limited - Nomad and Joint Broker   +44 (0) 161 831 1512 
 Dan Bate / Jordan Warburton 
 Bryan Garnier & Co. Limited - Joint Broker      +44 (0)20 7332 2500 
 Dominic Wilson / Phil Walker 
 

About 4D

Founded in February 2014, 4D is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform that rationally identifies novel bacteria based on a deep understanding of function and mechanism. 4D's Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D has three clinical studies in progress, namely a Phase II clinical study of Blautix(R) in Irritable Bowel Syndrome, a Phase I/II study of MRx0518 in combination with KEYTRUDA(R) (pembrolizumab) in solid tumours and a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours. Other focus programmes include disease areas such as asthma and CNS disease.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGGCGDLUXDBGCG

(END) Dow Jones Newswires

June 20, 2019 05:38 ET (09:38 GMT)

Grafico Azioni 4d Pharma (LSE:DDDD)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni 4d Pharma (LSE:DDDD)
Storico
Da Apr 2023 a Apr 2024